| Description | Acarix AB is a Swedish medical technology company that develops innovative solutions
for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor
System, which has also received DeNovo approval from the FDA, is intended for patients
experiencing chest pain with suspected coronary artery disease and is designed to help
reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor
System uses advanced acoustics and AI technology to non-invasively rule out CAD in
less than 10 minutes, with at least 96% certainty.
Additional info from OTC:
Acarix AB is a Swedish medical technology company that develops innovative solutions
for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor
System, which has also received DeNovo approval from the FDA, is intended for patients
experiencing chest pain with suspected coronary artery disease and is designed to help
reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor
System uses advanced acoustics and AI technology to non-invasively rule out CAD in
less than 10 minutes, with at least 96% certainty. |
|---|